The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Accepteret manuskript, 459 KB, PDF-dokument
Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH). Methods: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94–8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47–12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00–1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00–1.89) and NHL (aIRR 2.57; 95% CI 1.16–5.68). There was no significant association between HBV and lung or anal cancer. Conclusions: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | HIV Medicine |
| Vol/bind | 23 |
| Udgave nummer | 6 |
| Sider (fra-til) | 585-598 |
| Antal sider | 14 |
| ISSN | 1464-2662 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
EuroSIDA has received funding from ViiV Healthcare LLC, Janssen Scientific Affairs, Janssen R&D, Bristol‐Myers Squibb Company, Merck Sharp & Dohme Corp, Gilead Sciences and the European Union's Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement no. 260694. The participation of centres from Switzerland has been supported by The Swiss National Science Foundation (grant 148522). The study is also supported by a grant (grant number DNRF126) from the Danish National Research Foundation and by the International Cohort Consortium of Infectious Disease (RESPOND). JMM received a personal 80:20 research grant from Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–2021.
Funding Information:
AM has received honoraria, speaker fees, travel support and/or consultancy funds from ViiV, Gilead and Eiland and Bonnin PC outside the submitted work. JMM has received consulting honoraria and/or research grants from AbbVie, Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare outside the submitted work. GW has received travel support and research grants from Gilead Sciences, ViiV and AbbVie outside the submitted work. JML has received consulting honoraria and/or research grants from ViiV Healthcare, Gilead Sciences and Janssen‐Cilag outside the submitted work. CD has received consultancies, speaker honoraria and travel grants from Gilead Sciences, MSD and ViiV Healthcare outside the submitted work. LP has received travel support from Gilead outside the submitted work. AB, KvB, MB, JM, MC, FM, CUF, BK, EB, EK, PD, AZ, JPV, OD, AnM and TB report no conflicts of interest.
Publisher Copyright:
© 2021 British HIV Association.
ID: 329431150